| abstract |
Triclabendazole (TCBZ) and fenbendazole (FBDZ) have been discovered to extend the lifespan of yeast cells (a model for apoptosis), increase protection for cells from oxidative stress, and protect against cell death caused by Parkinson's disease-related protein alpha- synuclein. Both triclabendazole and fenbendazole can be used to extend the lifespan of eukaryotic cells, protect cells from oxidative stress, and treat various neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, and Huntington's diseases) that involve toxic protein aggregates. Derivatives or metabolites of either TCBZ or FBDZ would have similar effects. Known metabolites of TCBZ include a sulfoxide (TCBZ-SO) and a sulfone (TCBZ- S02). Similar metabolites of FBDZ include a sulfoxide (FBDZ-SO) and a sulfone (FBDZ- S02). |